2 completed. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
Follow HAE: new trials by email Literature Review of HAE trials Research Report on HAE
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Long Term Safety Study of BCX7353 in Hereditary Angioedema BCX7353 - Hereditary Angioedema, HAE | Phase 2 / Phase 3 | Completed | BioCryst Pharmaceuticals | 387 | 2018-02-16 | 2023-06-18 |
| 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks BCX4161, Placebo - Hereditary Angioedema, HAE | Phase 2 / Phase 3 | Completed | BioCryst Pharmaceuticals | 110 | 2014-12-17 | 2025-11-17 |
Angioedema (2) · Cardiovascular Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Hereditary Complement Deficiency Diseases (2) · Hypersensitivity (2) · Hypersensitivity, Immediate (2) · Immune System Diseases (2) · Immunologic Deficiency Syndromes (2) · Primary Immunodeficiency Diseases (2) · Skin Diseases (2) · Skin Diseases, Vascular (2) · Skin and Connective Tissue Diseases (2) · Urticaria (2) · Vascular Diseases (2)
avoralstat (1) · berotralstat (1)
France (2) · Germany (2) · Hungary (2) · Italy (2) · United Kingdom (2) · United States (2) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · Denmark (1) · Hong Kong (1) · Israel (1) · New Zealand (1) · North Macedonia (1)
Henriette Farkas, MD (1) · Marc Riedl, MD MS (1)
PMID 34161665, PMID 35820771, PMID 36326435, PMID 36408587, PMID 38006972, PMID 38020288, PMID 40490218